Drug Overview

Sapanisertib is an experimental, highly advanced medication being developed to treat several types of cancer, including lung, breast, and ovarian cancer. It is a laboratory-made drug taken by mouth. Right now, it is only available to patients participating in approved clinical research trials and cannot be bought at a regular pharmacy.

• Generic name: Sapanisertib (also known in research as MLN0128, INK128, TAK-228, or CB-228)
• US Brand names: None (Investigational drug)
• Drug Class: Dual mTORC1/mTORC2 inhibitor, Small molecule kinase inhibitor
• Route of Administration: Oral (taken by mouth as a capsule or tablet)
• FDA Approval Status: Investigational. It recently received FDA Fast Track designation for specific types of lung cancer, but it is not yet fully approved for standard public use.

What Is It and How Does It Work? (Mechanism of Action)

Sapanisertib is a Targeted Therapy and functions as a Smart Drug. Traditional chemotherapy attacks all fast-growing cells in the body, which causes many side effects. Sapanisertib is different because it is designed to seek out and block specific communication pathways that only cancer cells use to grow and survive.

At the molecular level, sapanisertib targets a very important protein complex inside the cell called the mammalian target of rapamycin (mTOR). The mTOR pathway acts like a central command station, telling the cell to consume energy, grow, and divide. In many cancer cells, this command station is broken and stuck in the “on” position, causing the tumor to grow out of control.

Older drugs only blocked one part of this command station (called mTORC1). When that happened, the cancer cells would often find a backdoor way to survive by using a second part of the command station (called mTORC2). Sapanisertib is a “dual inhibitor.” This means it blocks both mTORC1 and mTORC2 at the same time. By completely shutting down both parts of the command station, sapanisertib cuts off the cancer cell’s energy and growth signals, forcing the cancer cell to stop dividing and eventually die.

FDA-Approved Clinical Indications

Because sapanisertib is still in the testing phase, it does not have official FDA-approved indications yet. It is currently being studied for the following uses:

Oncological uses

• Investigational treatment for advanced squamous non-small cell lung cancer, especially tumors with a specific genetic change called an NRF2 mutation.
• Investigational treatment for advanced breast cancer, often combined with hormone therapies.
• Investigational treatment for platinum-resistant ovarian cancer.
• Investigational treatment for other solid tumors like endometrial cancer and glioblastoma.

Non-oncological

• None at this time.

Dosage and Administration Protocols

Because sapanisertib is an investigational drug, the dose a patient receives depends on the specific clinical trial they are joining. The table below shows the standard doses used in recent clinical trials.

Dose Adjustments:

If a patient develops severe side effects, the clinical trial doctors will lower the dose or pause the medication. Because sapanisertib is processed by the liver, patients with severe hepatic (liver) insufficiency might need lower doses or might be excluded from the trial. Patients taking medications that interfere with liver enzymes (like CYP3A4 inhibitors) will also need careful dose adjustments.

Clinical Efficacy and Research Results

Clinical trials from 2020 to 2025 have shown promising numerical data for sapanisertib, particularly when used for hard-to-treat cancers.

In a recent Phase 2 trial (the DICE trial) for patients with platinum-resistant ovarian cancer, combining sapanisertib with the chemotherapy drug paclitaxel improved progression-free survival compared to using paclitaxel alone. The combination therapy resulted in a 34 percent reduction in the risk of disease progression or death. The trial showed that patients on the combination therapy had their disease stabilized for over 5 months on average.

In another Phase 2 trial for patients with advanced squamous non-small cell lung cancer that carried the NRF2 mutation, sapanisertib showed an overall response rate of 27 percent. This means the tumors shrank significantly in more than one-fourth of the patients. The median progression-free survival in this group was 8.9 months, which is a very encouraging result for a cancer that usually does not respond well to standard treatments.

Safety Profile and Side Effects

Like all strong targeted therapies, sapanisertib can cause side effects. Patients in clinical trials are closely watched by their medical team.

Black Box Warning:

Because this drug is investigational and not available on the regular market, it does not currently have an official FDA Black Box Warning.

Common side effects

These side effects are seen in greater than 10 percent of patients:

• High blood sugar (hyperglycemia)
• Feeling extremely tired or weak (fatigue)
• Nausea, vomiting, and loss of appetite
• Diarrhea
• Mild skin rashes

Serious adverse events:

• Severe high blood sugar that requires medical treatment
• High levels of fats in the blood (hypertriglyceridemia)
• Severe gastrointestinal disorders and dehydration
• Acidosis (too much acid in the blood)

Management strategies:

Because high blood sugar is a very common effect of blocking the mTOR pathway, patients may need to start taking diabetes medications (like metformin) or change their diet while on the trial. If nausea or diarrhea occurs, doctors will prescribe anti-nausea and anti-diarrhea medicines. If side effects become too severe, the research team will pause the sapanisertib treatment until the patient recovers.

Research Areas

Research Areas:

While sapanisertib is primarily being studied to shrink tumors, it is also highly relevant to cancer stem cell research. Cancer stem cells are the stubborn hidden cells that survive traditional chemotherapy and cause the cancer to return. Researchers have found that these stem cells heavily rely on the mTOR signaling pathway to stay alive. By completely blocking both mTORC1 and mTORC2, researchers are investigating if sapanisertib can destroy these root cells. If successful, this could eventually be combined with regenerative medicine or immunotherapies to prevent the cancer from ever growing back.

Patient Management and Practical Recommendations

Patients taking sapanisertib in a clinical trial must follow strict safety rules.

Pre treatment tests to be performed:

• Fasting blood glucose and Hemoglobin A1c tests to check for hidden diabetes or blood sugar issues.
• Complete blood count tests to measure red cells, white cells, and platelets.
• Comprehensive metabolic panels to ensure the liver and kidneys are working well.
• Genetic testing of the tumor to see if it has specific mutations (like the NRF2 mutation) that respond best to the drug.

Precautions during treatment:

Patients must monitor their blood sugar at home, even if they do not have diabetes. Any sudden spikes in blood sugar, extreme thirst, or frequent urination must be reported to the doctor right away.

Do’s and Don’ts list:

• Do take the medication at the same time every day, exactly as instructed by your trial doctor.
• Do drink plenty of water to stay hydrated, especially if you have diarrhea.
• Do report any new skin rashes, fatigue, or stomach pain to your medical team immediately.
• Don’t eat grapefruit or drink grapefruit juice, as it can block the liver enzymes that process the drug and cause dangerous side effects.
• Don’t start any new over-the-counter vitamins, herbal supplements, or medicines without asking your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Sapanisertib is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your cancer treatment or participating in a clinical research study.